Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | STK16 | O75716 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.56 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.56 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.55 |
| ▸ | JAK1 | P23458 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 3/20 | 0.55 |
| ▸ | MARK3 | P27448 | 3/20 | 0.53 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.53 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901171 | 0.87 | TBK1 (0.66) | PLK4CDK1KDRTBK1NUAK1 | |
| SCHEMBL270947 | 0.86 | PLK4 (0.57) | PLK4CDK1KDRJAK3JAK2 | |
| SCHEMBL14536298 | 0.82 | TBK1 (0.67) | PLK4CDK1KDRTBK1NUAK1 | |
| SCHEMBL29370869 | 0.81 | CDK1 (0.63) | PLK4CDK1KDRTBK1NUAK1 | |
| SCHEMBL13252157 | 0.81 | CDK1 (0.56) | PLK4CDK1KDRTBK1NUAK1 | |
| SCHEMBL4875509 | 0.80 | PLK4 (0.64) | PLK4CDK1KDRTBK1NUAK1 | |
| SCHEMBL763619 | 0.78 | SYK (0.62) | — | |
| SCHEMBL28153587 | 0.78 | PLK4 (0.56) | PLK4CDK1KDRTBK1NUAK1 | |
| SCHEMBL20516557 | 0.77 | RIPK2 (0.59) | PLK4CDK1KDRTBK1NUAK1 | |
| SCHEMBL266638 | 0.77 | BRD4 (0.65) | PLK4KDRTBK1NUAK1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | PLK4 440/4885CDK1 132/4885KDR 419/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | PLK4 440/4885CDK1 132/4885KDR 419/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | PLK4 440/4885CDK1 132/4885KDR 419/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | PLK4 440/4885CDK1 132/4885KDR 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.